open access

Vol 77, No 1 (2009)
REVIEWS
Published online: 2008-12-19
Submitted: 2013-02-22
Get Citation

Tuberculosis after renal transplantation

Anna Korzeniewska, Tomasz Dyła, Monika Kosacka, Renata Jankowska
Pneumonol Alergol Pol 2009;77(1):61-65.

open access

Vol 77, No 1 (2009)
REVIEWS
Published online: 2008-12-19
Submitted: 2013-02-22

Abstract

Renal transplant recipients carry a relatively high risk of developing tuberculosis (TB). In most cases, active TB is the result of reactivation of a latent infection and is located in the lungs. In these patients, clinical presentation of TB can often be atypical and there is a high risk of dissemination and high mortality rates. Therefore, the use of invasive procedures for proper diagnosis is recommended, as well as anti-tuberculosis therapy instituted whenever there is a strong suspicion of TB on clinical grounds, even without microbiological evidence. The treatment of active TB in renal transplant recipients should be the same as in the general population. To avoid graft rejection, blood levels of calcineurin inhibitors should be monitored closely. Prophylaxis is recommended for high-risk patients.

Abstract

Renal transplant recipients carry a relatively high risk of developing tuberculosis (TB). In most cases, active TB is the result of reactivation of a latent infection and is located in the lungs. In these patients, clinical presentation of TB can often be atypical and there is a high risk of dissemination and high mortality rates. Therefore, the use of invasive procedures for proper diagnosis is recommended, as well as anti-tuberculosis therapy instituted whenever there is a strong suspicion of TB on clinical grounds, even without microbiological evidence. The treatment of active TB in renal transplant recipients should be the same as in the general population. To avoid graft rejection, blood levels of calcineurin inhibitors should be monitored closely. Prophylaxis is recommended for high-risk patients.
Get Citation

Keywords

tuberculosis; renal transplantation; immunosuppression

About this article
Title

Tuberculosis after renal transplantation

Journal

Advances in Respiratory Medicine

Issue

Vol 77, No 1 (2009)

Pages

61-65

Published online

2008-12-19

Bibliographic record

Pneumonol Alergol Pol 2009;77(1):61-65.

Keywords

tuberculosis
renal transplantation
immunosuppression

Authors

Anna Korzeniewska
Tomasz Dyła
Monika Kosacka
Renata Jankowska

References (38)
  1. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis. 1998; 27(5): 1266–1277.
  2. Vandermarliere A, Van Audenhove A, Peetermans WE, et al. Mycobacterial infection after renal transplantation in a Western population. Transpl Infect Dis. 2003; 5(1): 9–15.
  3. Lezaic V, Radivojevic R, Radosavljevic G, et al. Does tuberculosis after kidney transplantation follow the trend of tuberculosis in general population? Ren Fail. 2001; 23(1): 97–106.
  4. European best practice guidlines for renal transplantation. Section : Long-term management of the transplant recipient. IV 7 2 Late infections Tuberculosis Nephrol Dial Transplant. 2002; 17: 39–43.
  5. Sayiner A, Ece T, Duman S, et al. Tuberculosis in renal transplant recipients. Transplantation. 1999; 68(9): 1268–1271.
  6. Queipo JA, Broseta E, Santos M, et al. Mycobacterial infection in a series of 1261 renal transplant recipients. Clin Microbiol Infect. 2003; 9(6): 518–525.
  7. Jereb JA, Burwen DR, Dooley SW, et al. Nosocomial Outbreak of Tuberculosis in a Renal Transplant Unit: Application of a New Technique for Restriction Fragment Length Polymorphism Analysis of Mycobacterium tuberculosis Isolates. Journal of Infectious Diseases. 1993; 168(5): 1219–1224.
  8. Peters TG, Reiter CG, Boswell RL. Transmission of tuberculosis by kidney transplantation. Transplantation. 1984; 38(5): 514–516.
  9. Durlik M, Klinger M, Lao M, Więcek A, Rowiński W. Zalecenia dotyczące leczenia immunosupresyjnego po przeszczepieniu narządów unaczynionych. In: Rowiński W, Durlik M. ed. Fundacja Zjednoczeni dla Transplantacji. , Warszawa 2006: 13–47.
  10. Chen CH, Lian JD, Cheng CH, et al. Mycobacterium tuberculosis infection following renal transplantation in Taiwan. Transpl Infect Dis. 2006; 8(3): 148–156.
  11. Higgins RM, Cahn AP, Porter D, et al. Mycobacterial infections after renal transplantation. Q J Med. 1991; 78(286): 145–153.
  12. Kircher B, Lätzer K, Gastl G, et al. Comparative in vitro study of the immunomodulatory activity of humanized and chimeric anti-CD25 monoclonal antibodies. Clin Exp Immunol. 2003; 134(3): 426–430.
  13. Van Gelder T, Warlé M, Ter Meulen RG. Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice? Drugs. 2004; 64(16): 1737–1741.
  14. Qunibi WY, al-Sibai MB, Taher S, et al. Mycobacterial infection after renal transplantation--report of 14 cases and review of the literature. Q J Med. 1990; 77(282): 1039–1060.
  15. Drobniewski FA, Ferguson J. Tuberculosis in renal transplant units. Nephrol Dial Transplant. 1996; 11(5): 768–770.
  16. Rowińska D, Durlik M, Gradowska L, et al. Gruźlica u chorych po przeszczepieniu nerki. Pneumonol Alergol Pol. 1994; 62: 272–279.
  17. Apaydin S, Altiparmak MR, Serdengeçti K, et al. Mycobacterium tuberculosis infections after renal transplantation. Scand J Infect Dis. 2000; 32(5): 501–505.
  18. Hall CM, Willcox PA, Swanepoel CR, et al. Mycobacterial infection in renal transplant recipients. Chest. 1994; 106(2): 435–439.
  19. Chou KJ, Fang HC, Bai KJ, et al. Tuberculosis in maintenance dialysis patients. Nephron. 2001; 88(2): 138–143.
  20. Fang HC, Lee PT, Chen CL, et al. Tuberculosis in patients with end-stage renal disease. Int J Tuberc Lung Dis. 2004; 8(1): 92–97.
  21. Petrie JJ, Rigby RJ, Hawley CM, et al. Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation. Transplantation. 1988; 45(1): 68–73.
  22. Green M, Avery RK. Mycobacterium tuberculosis. American Journal of Transplantation. 2004; 4: 37–41.
  23. Rowińska-Zakrzewska E, Kuś J. Choroby układu oddechowego. Wydawnictwo PZWL, Warszawa 2004: 548–551.
  24. Cassidy MJ, Van Zyl-Smit R, Pascoe MD, et al. Effect of rifampicin on cyclosporin A blood levels in a renal transplant recipient. Nephron. 1985; 41(2): 207–208.
  25. Buffington GA, Dominguez JH, Piering WF, et al. Interaction of rifampin and glucocorticoids. Adverse effect on renal allograft function. JAMA. 1976; 236(17): 1958–1960.
  26. Aguado JM, Herrero JA, Gavaldá J, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation. 1997; 63(9): 1278–1286.
  27. López-Montes A, Gallego E, López E, et al. Treatment of tuberculosis with rifabutin in a renal transplant recipient. Am J Kidney Dis. 2004; 44(4): e59–e63.
  28. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA. 1999; 281(11): 1014–1018.
  29. Periera BJ, Wright TL, Schmid CH, et al. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation. 1995; 60(8): 799–805.
  30. Genescà J, Vila J, Córdoba J, et al. Hepatitis C virus infection in renal transplant recipients: epidemiology, clinical impact, serological confirmation and viral replication. J Hepatol. 1995; 22(3): 272–277.
  31. John GT, Shankar V, Abraham AM, et al. Risk factors for post-transplant tuberculosis. Kidney Int. 2001; 60(3): 1148–1153.
  32. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ. 1982; 60(4): 555–564.
  33. Pape JW, Jean SS, Ho JL, et al. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet. 1993; 342(8866): 268–272.
  34. Whalen C, Johnson J, Okwera A, et al. A Trial of Three Regimens to Prevent Tuberculosis in Ugandan Adults Infected with the Human Immunodeficiency Virus. New England Journal of Medicine. 1997; 337(12): 801–808.
  35. Agarwal SK, Gupta S, Dash SC, et al. Prospective randomised trial of isoniazid prophylaxis in renal transplant recipient. Int Urol Nephrol. 2004; 36(3): 425–431.
  36. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society, MMWR. 2000; 49: 1–51.
  37. Rowińska-Zakrzewska E. Gruźlica w praktyce lekarskiej. Wydawnictwo PZWL, Warszawa 2000: 242–245.
  38. Kobashi Y, Mouri K, Obase Y, et al. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients. Eur Respir J. 2007; 30(5): 945–950.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl